Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee’s Pharma Subsidiary In-Licenses Dyax Drug for China Use

publication date: Feb 8, 2013
CVie Therapeutics, a subsidiary of Hong Kong-based Lee's Pharma, has in-licensed China rights to Kalbitor®, a treatment for hereditary angioedema, from Dyax Corp. of the US. CVie will be responsible for securing regulatory approval of the drug in China. It has been marketed in the US since 2010. Lee’s markets western drugs for sale in mainland China; it also has an in-house R&D drug development operation. More details....

Stock Symbols: (HK: 00950) (NSDQ: DYAX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital